/NOT FOR DISTRIBUTION TO U.S. MEDIA/
Shire
MONTRÉAL,
For any treatment to be effective, patients must take their medication as prescribed by their doctor. In many cases patients stop taking their medication as soon as their disease symptoms lessen or when their prescription runs out. This often leads to a reduction in the efficacy of their medication.
Now, Canadians prescribed MEZAVANT will be able to receive convenient reminders either by phone, email or SMS text message.
"Our goal with MEZADVICE is to provide reassurance and support to patients who have been prescribed MEZAVANT," states
About Shire plc & Shire
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
Shire
For further information on Shire, please visit the Company's Web site: www.shire.com
* MEZADVICE is a trade-mark of Shire Canada Inc. (xx) MEZAVANT is a registered trade-mark used under licence from Giuliani International Limited
For further information: Chrome Communications, T: (905) 567-1406 or Toll Free: 1-888-867-1406; Alon Barmapov, ext. 223, C: (647) 405-1352, [email protected]; Amanda Webster, ext. 222, C: (647) 339-7096, [email protected]
Share this article